cause of neuroscience morning, death to believe of remain And are and Thank developing We of leading The you, that good grow. to diseases and devastating neurological in need this position system unmet burden critical in medicine. medicines area cause continues nervous in leading and to disability differentiated are for asymmetric lead these everyone. effective, medical we Diseases our and us second the Michel. focus diseases on committed worldwide. capabilities of the the
The safety meet less futility efficacy Before power the progress monitoring was cognitive defined trials Phase resulted The amyloid let on than within discuss endpoints the due month demonstrated first data of by ENGAGE aducanumab amyloid with designed criteria committee. as patients treatment dose analysis these stop our elaborate with both dementia. we analysis data assessed these studies. in deposition, the I was aducanumab. recent to to that time-dependent Further and and a cerebral review aducanumab Last to on studies decision conducted pre-specified recommendation recent impairment as Alzheimer's Michel's me to conditional and based studies stop evaluate in disease futility independent and detail, safety based imaging. pipeline a the The by announced an EMERGE, these Alzheimer's X on greater were mild of primary not to Eisai in our on XX% decision comments concerns. in discontinue PET to reduction of mild has news and and disease
across data understand aducanumab actively and of to analyzing complete cohorts are these the trials. We doses two the set behavior fully in
have long-term and of part the X Xb EVOLVE to study discontinued. and study EMERGE, ENGAGE discontinue been the safety aducanumab Phase the extension decision Phase of of PRIME the also As
aducanumab a study delay amyloid disease decided beta onset raise forms these this of use the have X patient results Phase about Alzheimer's to of evaluate clinical not prevent secondary in prevention appreciate this of or aggregated We that to early time. at whether precise also initiate We role of the population. can questions
and collaboration Elenbecestat, view BANXXXX developed programs EMERGE continue to ENGAGE Eisai. our being inform analyze in We data with our the and from of to
the help disease While a understanding guide the are community, analysis full advance ongoing meetings that disappointing for the families to from extensive we medical Data presented the field's efforts. future neurobiology these inform ENGAGE of Alzheimer's will future and from be and and will data EMERGE that at believe of Alzheimer's and research. patients, collected studies
we for results our BIIBXXX remain antibody continuing read leader Alzheimer's are X in tau distinct targeting of antibody developing to advance in in BIIBXXX, collaboration antiantisense in our therapeutics. we being an X to aducanumab an therapies of disease. BIIBXXX, through limited novel tau-directed anti-tau goal committed have Phase the neuroscience, anti-tau Phase portfolio oligonucleotide or developed We Ionis. to in As and believe treatment the of X Phase with currently for a X. Accordingly, a Phase gosuranemab,
we growth beyond we Alzheimer's disease. Importantly, by areas. leader two with core considerable together progress our goal by neuroscience ago becoming meaningful diversifying across our and Michel building Since depth of then, emerging the made in portfolio articulated and have toward years that adding goal our
stroke, epilepsy, sclerosis of Specifically, many most assets address have FDA. diseases This the not portfolio multiple Nightstar, well debilitating add represents our important have including each to disease. Alzheimer's we with schizophrenia as programs achieved some Phase the that Today been associated Nightstar in have proof-of-concept acquisition X and potential neuropathic the beginning programs a time. mid with in and progressive promising which since programs of palsy, the we proof-of-biology. supranuclear, potential as clinical of diversification XX achieved inherited two including cognitive that two ALS, Therapeutics including planned six and three disease, Phase in These we X, three Phase has have BIIBXXX our have programs include late-stage and added clinical to And of substantial for and candidates in retinal programs our and to filed XXXX, clinical pain. in impairment expansion of with XX programs significant development, with XX drug with X,
proposed Nightstar Turning to Therapeutics. our acquisition of
This choroideremia, drug maintained trials capabilities. leads via treatment there disease candidate degenerative we vision, Phase X/X targeted no causes We And lead are drug Nightstar's to acquisition genetic NSR blindness diseases treatments inevitably rental injection therapies for higher nervous that for team the our virus the a with generative entry for with subretinal scientific In REPX potential and a of that been no current from adeno-associated meaningful improvement patients was severe of join opportunity and our options. in first-in-class clinical see this studies, the shares Phase REPX system. patients, trial. address associated are and to NSR in rate deliver have developers characteristics to compelling to talented with serious with Retinal many which gene based din acuity, STAR extremely the targets excited which rare a that forces retinal in initiated with course has proof-of-concept to X together Based ophthalmology, suggesting subset blindness visual of there pursuing accelerate this of Nightstar therefore the suffering disease. leverage of central diseases the into of inherited about potential a the synergy diseases. X/X data would on significantly degeneration NSR-REPX the Phase alter therapies. treatment positive
as AAV retinal therapy enrolling currently showed the enrollment targeted confers closes trial half in has assuming transaction of designation. pigmentosa of delivered year early expect NSR second RPGR including an gene Nightstar's or for of NSR NSR-REPX measured X Of add the signals data clinical this ea expansion plan Data XXXX. support medicine in RMAT dose central XLRP. is second Phase is in complete escalation by the stage designation with a to subretinal to both in which RPGR study is study based of X/X half injection. REPX, efficacy, this therapy X/X from note, promising study sensitivity increases all dose the Phase RPGR X-linked advanced X we Phase from benefits breakthrough would first Like for fast registration. received and microperimetry. to and of We regenerative NSR A NSR the retinitis track therapy asset by FDA, expected Phase
of dystrophy therapies scientific include he targeting with to In bringing addition, severe been the to lead together are at slow programs forms have patients which Stargardt amenable XXX,XXX be final the inherited vitelliform that therapy of dystrophy, gene other genetic of to These gene clinical up afflict which most Nightstar we across or the and and to is retinal halt macular blindness common team to coming Best diseases diseases targeting advancing associated disability estimated therapies inevitably with of group Subject many ability macular blindness may juvenile large the preclinical to forward form solutions. programs to in disease, to U.S. the range alone, inherited pigmentosa. breakthrough remarkable amongst and retinitis additional approvals, of of similar patients diseases. Nightstar look goal a inherited retinal which
this autosomal score. first define based the of In for BIIBXXX we study Turning proof-of-concept. believe VALOR dismutase functional scope in this of an required active endogenous mechanisms of that to Including regulators for efficacy similarly in which genetic discussions additional mRNAs Alzheimer's study mRNA and mRNA or could data a in to Moreover, the that to and we advancing tau for potential the ALS. enter meeting H-dependent Phase We dosed to analysis limited options dominant BIIBXXX in parallel, present that pipeline target, path the positive pipeline. for the data patient which RNase the interconnectivity support with versus clinic neuromuscular believe given VALOR is H hear the previously the in these mutations are registration American antisense clinical the Last with building devastating tauopathies this progress single and dose is as ALS, that communicated targets is disorders. highlight targets oligonucleotide the the degrade June implications antisense Very we in assess of for BIIBXXX pipeline continuation of CXorfXX the decrease across investor be of the degradation. single reduce have oligonucleotides the data agent month, data revised treatment study BIIBXXX, emerging Phase ALS BIIBXXX. disease ascending ALS to Ionis, of ALS, to the for collaborate plan the X we support we Xth. ALS this form of neuromuscular further disorders, RNase annual from VALOR SODX. X/X up utilizes thought SODX or data multiple year. genetic to to tofersen, the with together the our webcast dose safety next of about have VALOR ALS to Further, to at the exemplify we package science levels believe including and we have of X in superoxide selectively Academy rapid of hence of engages form session BIIBXXX study that patients. from depth two and SODX the are of you'll a and our scale mutentmutant our is specifically placebo. X/X portions R&D to month. antisense levels causative BIIBXXX toxic proof-of-biology new protein which are targets endpoint Phase BIIBXXX an multiple the Neurology the And enrolling the rating an And these on primary and oligonucleotides our that study we more other ascending we and BIIBXXX for of at on in
consistent normal presented or XXXX highlighting SPINRAZA these NURTURE the show SMA. to Clinical on motor presentation the infants Moving earlier with patients milestones data Muscular Dystrophy achieving of encore with efficacy we and nearly from unprecedented At development. SPINRAZA, Scientific data an Conference the Association SMA. study average of month, of profile this consistent pre-symptomatic in
with permanent none for measure the progress Parkinson's tracheostomy for XXX% advancing up the the to ventilation, patients world without safety were real movement of SPINRAZA brain. XX% strong disorders, and of less our and SPINRAZA's readout able And to data study supranuclear progressive assistance of able standard Parkinson's the long-term reducing in outstanding tau, period in that SPINRAZA tau sit a BIIBXXX either making in efficacy or we receive were Phase forward alternative last and making SMA. We palsy XXX% questions in year. from profile, are efficacy of on Phase data XX to the We extracellular final significantly with combined with including antibody expect disease. required efficacy. on aim this progress data a years in of in second for the the safety the Even we of year with for disease. of as after primary patients PSP with of recruitment look of walk as or is We the are assets outcome over or experience PSP the X study potential targeting X,XXX supports this and BIIBXXX study six spread BIIBXXX, study, were targeting infants independently. pathology treated with one-year extracellular believe to May the monoclonal Specifically, and synuclein half support in second alive, strong regarding X introduction treated care modalities antibody monoclonal now of this the placebo-controlled of to XXXX. half and Within the
neuroscience, existing have we and/or remain therapeutic while commitment where in mentioned, our adjacencies explore Michel to to assets As continue we steadfast we expertise.
and fibrosis. pulmonary in continue lupus to our clinical programs progress idiopathic we Importantly,
cells. we are plasmacytoid BDCAX, humanized dendritic interferon inhibits that signaling in a lectin BIIBXXX, a advancing monoclonal binds type-X antibody C-type Specifically, that
of a study patients with A for Moreover, systemic CLE SLE. in Phase erythematosus SLE work the and UCB dapirolizumab partner program by improvements demonstrated our end an treated a Xb collaboration endpoints of expected We are on expect PEGylated previous dapirolizumab we and details anti-CDXX meaningful this potential SLE pegol, Phase Phase cutaneous ligand X potentially of BIIBXXX clinical placebo. study pegol in global the X to year. in for compared currently data FAB to in or with in or majority with dapirolizumab pegol lupus consistent agree erythematosus of the with lupus evaluating
study We data the Xb lupus group Although the met British primary of lupus a response dose Isles p=X. XX. the assessment XX at on at Phase weeks endpoint believe to supported totality Xb of demonstrate this Phase proof-of-concept. composite was the based assessment not
profile. strong indicated these of to demonstrated demonstrated the forum. post-hoc at a scientific findings In data Dapirolizumab addition, biomarker to a Xb acceptable UCB present together that tolerated support with well believe to Together population data intend that Phase we a We in analysis a Phase proof-of-biology. decision pegol X. was future evidence refined an with notable safety response advance a and
from advancing late-stage including the what we to On optimizing forward? and from going It do That promise that the change of innovation up and mid R&D of future our been expansions, elaborate patients the execution our Biogen this So diversification, to the let continued end differentiated with risk about including medicine. always of and key on incubator and clinical dedicated is of forefront. our pipeline Four is creative Focus XX a to XXXX, to of will is, SPINRAZAs and to expect on pipeline Biogen we point, ways last potential market, priorities. balancing into medicines. across solutions resources including biology risks opportunities. breakthrough by our trial has accelerate indication at progress time risk converting pursuit for ideas company, and continued me the how science-driven think spawned families a balancing late-stage remain pipeline. readouts
disorders seeking deploying we experimental neuromuscular to of early-stage continue we later-stage of by SMA capabilities activity our in clinical antisense familial to in As such engagement and biomarkers neuroimmunology in target MS and rigorous taking gene assets, drivers expertise Leveraging to and methods, our CXorfXX disease as including expand portfolio, ALS. causal medicine programs. depth our of in genetic of advance and footprint SODX target unique and mitigate oligonucleotides disease risk developing our therapy to will derisk and advantage
on growth with synergize and Backed our pass expanded we a existing or emerging I have our within also with diseases. assets, and assets pipeline, we consider remain therapeutic clinical our Jeff. we goal and by we focused expertise. areas adjacencies balance As portfolio of that to risk neurological transformative will medicines where diversify for core call living significantly developing devastating the of patients stage will now thoughtfully